Second primary cancers in breast cancer patients in Slovenia
Second primary cancers in breast cancer patients in Slovenia
复制标题
DOI：
10.1023/a:1018487506546
复制
发表时间：
1997-09-01
影响因子：
2.3
通讯作者：
PompeKirn, V
中科院分区：
文献类型：
--
作者：
Volk, N;PompeKirn, V
来自斯洛文尼亚癌症登记处的数据被用于一项队列研究，以确定原发性乳腺癌患者的第二原发癌症发病率是否与一般人群的预期发病率不同。长期幸存者得到了特别关注。第二原发性癌症的预期数量是通过将斯洛文尼亚妇女相应年龄和日历期特定癌症发病率乘以适当的高危人年数来计算的。第二原发癌的风险以标准化发病率比（SIR）表示。在1961- 1985年期间新诊断并随访至1994年底的8,917例患者中，547例（6.2%）发展为第二原发性癌症，而410例（4.7%）是预期的（SIR = 1.3, 95%置信区间[CI] = 1.2-1.4）。年轻患者的风险更高。在长期幸存者中，第二原发性乳腺癌（SIR = 1.4, CI = 1.1-1.7）、肺癌（SIR = 1.6, CI = 1.1-2.3）、黑色素瘤（SIR = 2.7, CI = 1.5-4.4）和非黑色素瘤皮肤癌（SIR = 2.0, CI = 1.6-2.4）、子宫癌（SIR = 1.6, CI = 1.2-2.1）、卵巢癌（SIR = 2.3, CI = 1.7-3.0）和甲状腺癌（SIR = 2.5, CI = 1.2-4.6）的风险显著增加。我们的研究结果证实了在欧洲、美国和日本进行的几项队列研究的结果，表明乳腺癌患者应仔细监测第二原发癌症的发生。
Data from the Cancer Registry of Slovenia were used in a cohort study to determine whether the incidence of second primary cancers in patients with first primary breast cancer differs from the incidence expected in the general population. Special interest was given to long-term survivors. The expected numbers of second primary cancers were calculated by multiplying the number of appropriate person-years at risk by the corresponding age- and calendar-period-specific cancer incidence rates for women in Slovenia. The risk of a second primary cancer was expressed as the standardized incidence ratio (SIR). Of the 8,917 patients newly diagnosed in the period 1961-85 and followed-up to the end of 1994, 547 (6.2 percent) developed second primary cancers, whereas 410 (4.7 percent) were expected (SIR = 1.3, 95 percent confidence interval [CI] = 1.2-1.4). The risk was higher among younger patients. In long-term survivors, the risk was increased significantly for second primary cancer of the breast (SIR = 1.4, CI = 1.1-1.7), lung cancer (SIR = 1.6, CI = 1.1-2.3), melanoma (SIR = 2.7, CI = 1.5-4.4) and non-melanoma skin cancers (SIR = 2.0, CI = 1.6-2.4), corpus uteri cancer(SIR = 1.6, CI = 1.2-2.1), ovarian cancer(SIR = 2.3, CI = 1.7-3.0), and thyroid cancer (SIR = 2.5, CI = 1.2-4.6). Our results confirm the findings of several cohort studies carried out in Europe, the United States, and Japan, indicating that breast cancer patients should be monitored carefully for the occurrence of second primary cancers.